-
Sarepta Therapeutics Announces Results from Part 2 of EMBARK Study of ELEVIDYS
Sarepta Therapeutics, Inc. has announced positive topline results from Part 2 of EMBARK, the company’s […]
-
Update from PPMD’s 2025 Duchenne Healthcare Professionals Summit
PPMD recently convened over 360 healthcare professionals, researchers, and industry partners, including representatives from the […]
-
FDA awards fast track designation to DM1 treatment DYNE-101
The U.S. Food and Drug Administration (FDA) has granted fast track designation to DYNE-101, a […]
-
What success looks like for me as a DMD parent
Parenting is the most challenging job I’ve ever had. When my role as a parent […]
-
Avidity plans to submit for FDA Accelerated Approval for Duchenne exon 44 skipping at the end of 2025; Open-label extension trial is still recruiting
Amenable to skipping exon 44 Avidity Biosciences, which received early funding from CureDuchenne, plans to […]
-
The CureDuchenne International Outreach Program: Expanding Duchenne Care Beyond Borders
By Debra Miller, Founder and CEO of CureDuchenne Duchenne International Outreach: Bridging Gaps in Duchenne […]
-
Corticosteroid at low dose may help with muscle damage, inflammation
Once a week treatment with a corticosteroid was seen to lower some biomarkers of muscle […]
-
Race to End Duchenne Kicks Off 20th Anniversary at Walt Disney World Marathon Weekend
The Race to End Duchenne program is celebrating our 20th anniversary in 2025, and we […]
-
Stuck in limbo with both accessible vans out of commission
I live in rural Nebraska with my husband and our seven children. Three of them […]
-
Advance the Research Evolution with The Duchenne Registry
Everyone can help advance the research evolution for Duchenne and Becker. Bringing data sources together […]
